Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIA SH3 domain ER export factor 2 (MIA2) is a membrane-associated, SH3-domain containing protein encoded by the MIA2 gene, primarily functioning as a receptor in the endoplasmic reticulum involved in the export of large cargo such as pre-chylomicrons and pre-very low-density lipoproteins (pre-VLDLs)[4]. MIA2 is part of a gene family that includes transcript variants specific to melanoma inhibitory activity 2, cTAGE5, and TANGO1-like isoforms, which reflects the gene’s complex splicing and multifunctional nature. It acts as a cargo receptor coordinating with other ER exit site proteins to facilitate vesicle-mediated transport of select proteins and lipoproteins from the ER to the Golgi apparatus[4]. Disease roles are implicated in various cancers—especially as a marker in melanoma, meningioma, and lymphoma[4]. While it is designated by multiple aliases (CTAGE5, TALI, MEA6, among others), its key biological functions are centered on protein trafficking within secretory pathways. There are currently no approved therapeutics specifically targeting MIA2, and its mechanism of action in pathologies remains an active area of research[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MIA SH3 domain ER export factor 2 (MIA2).